Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

A Decision Support Tool for the Discontinuation of Disease Modifying Therapies in Multiple Sclerosis

Award Number: R21HS029219
ORGANIZATION: AGENCY FOR HEALTH CARE RESEARCH AND QUALITY
OPDIV: AHRQ
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2023
PERIOD OF PERFORMANCE END DATE: 07/31/2025

Group Awards By:

View Award Description

A Decision Support Tool for the Discontinuation of Disease Modifying Therapies in Multiple Sclerosis - Project summary The treatment of multiple sclerosis (MS) has been transformed with the introduction of disease-modifying therapies (DMTs), but these medications DMTs have known risks and are a significant financial burden for many people with MS and for the healthcare system as a whole. Nationally, prescription drugs account for 10- 15% of total healthcare spending, but, for people with MS, prescription drugs account for more than two-thirds of their total healthcare expenditures. The benefits of DMTs are clear early in the disease course, where they have been shown to prevent relapses and the accumulation of lesions in the central nervous system. Later in the disease course, the combination of immunosenscence and a shift from widespread neuroinflammation to neurodegeneration results in diminished biological benefits of DMTs and a shift in the risk/benefit ratio in people with MS. The most common risks associated with DMTs are infections, which have been reported to be as high as 19.7 per 1000 person-years. Studies have also shown that infectious complications tend to increase with both age and increased years of DMT exposure. For these biological, financial, and risk reasons discontinuation of DMT in certain individuals should be considered. There is a growing body of observational research supporting the notion that there is a safe time to discontinue DMTs with a low risk of recurrent disease activity. These studies all suggest that older patients who have been on a DMT for several years without active disease (no relapses, no new MRI lesions) have a low likelihood of recurrent disease activity after discontinuing DMT. Despite the growing evidence to support DMT discontinuation there is a lack of consensus from neurological societies and there is no standardized approach to this clinical decision. This study seeks to develop and validation a machine learning based point of care decision support tool to standardize the approach to MS DMT discontinuation. This study will develop the machine learning algorithm in a large retrospective clinical cohort and externally validate the tool in the “Discontinuation of disease modifying therapies in multiple sclerosis” (DISCOMS; NCT 03073603) randomized, controlled, single-blinded, clinical trial dataset during the R21 phase. In the R33 phase the validated point of care tool will be implemented through a pragmatic randomized clinical trial to assess the adoption and impact on clinical outcomes over 24 months. The overarching goal of this proposal is to create a decision support tool that will provide a standardized approach to DMT discontinuation resulting in a reduction in risk exposure and financial burden to people with MS.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	THE CLEVELAND CLINIC FOUNDATION	9500 EUCLID AVE, NA4	CLEVELAND	OH	44195	CUYAHOGA	USA	Research on Healthcare Costs, Quality and Outcomes	000	2	9/12/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $142,027 )
2024	2024	THE CLEVELAND CLINIC FOUNDATION	9500 EUCLID AVE	CLEVELAND	OH	44195	CUYAHOGA	USA	Research on Healthcare Costs, Quality and Outcomes	000	2	7/29/2024	NON-COMPETING CONTINUATION	$142,027
														Subtotal = $142,027

Issue Date FY: 2023 ( Subtotal = $132,947 )
2023	2023	THE CLEVELAND CLINIC FOUNDATION	9500 EUCLID AVE	CLEVELAND	OH	44195	CUYAHOGA	USA	Research on Healthcare Costs, Quality and Outcomes	000	1	7/25/2023	NEW	$132,947
														Subtotal = $132,947

Grand Total All Awards = $274,974

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A Decision Support Tool for the Discontinuation of Disease Modifying Therapies in Multiple Sclerosis

Award Number: R21HS029219

ORGANIZATION: AGENCY FOR HEALTH CARE RESEARCH AND QUALITY

OPDIV: AHRQ

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2023

PERIOD OF PERFORMANCE END DATE: 07/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer